Treatment of Injury or Neurodegenerative Disorders of the Enteric Nervous System (ENS) that cause Gastrointestinal Dysfunctions for which There is No Effective Therapy

Case ID:
C13755
Disclosure Date:
7/28/2015
JHU Ref. C13755
Title: Preconditioned BMSC Promote de novo Nerve Regeneration: Potential application in therapy of enteric nerve injury/disorders and vascularized composite allotransplantation (VCA)
 
UNMET NEED
Injury or neurodegenerative disorders of the enteric nervous system (ENS) cause gastrointestinal dysfunctions for which there is no effective therapy, therefore new and effective treatments are urgently needed. Researchers from Johns Hopkins and Hospital of Tongji Medical College developed a novel approach to precondition bone marrow-derived mesenchymal stem cells (BMSC) for effective treatment of injury or neurodegenerative disorders of the enteric nervous system (ENS). This technology can be easily modified and applied in VCA to accelerate the functional recovery of grafted limbs or face, a major obstacle in VCA due to slow and inefficient nerve growth and renervation.
 
PROBLEM SOLVED
Using the benzalkonium chloride (BAC)-induced rat gastric denervation model, the researchers transplanted bone marrow-derived mesenchymal stem cells (BMSC) to determine whether they could promote ENS neuron regeneration and if so, to elucidate the mechanism of action. BMSC isolated from the bone marrow of rats were preconditioned in vitro using fetal gut culture media containing glial cell-derived neurotrophic factor (GDNF), and transplanted subserosally into the denervated area of rat pylorus. The grafted BMSC survived and migrated from the subserosa to the submucosa 28 days after transplantation. PGP9.5/NSE/HuC/D/Tuj1-positive neurons were regenerated de novo in the denervated pylorus grafted with preconditioned BMSC. BMSC transplantation restored both basal pyloric contractility and electric field stimulation-induced relaxation.
 
MAJOR RESULTS
  • In vitro-preconditioned BMSCs promote de novo nerve regeneration and restore muscle contractility in pylorus-denervated rats through a GDNF positive feedback mechanism.
  • A novel concept for the mechanism responsible for BMSC-induced neuron regeneration.
  • Strong proof-of-principle for clinical application of BMSC-based therapy in ENS-related disorders.
  • BMSC can be delivered endoscopically anywhere in the GI tract
ASSOCIATED PUBLICATIONS
Stem Cells. 2015 Dec;33(12):3545-57
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
In vitro Pre-Conditioned Bone Marrow Derived-Derived Mesenchymal Stem Cells and Uses Thereof ORD: Ordinary Utility United States 15/227,831 10,478,458 8/3/2016 11/19/2019 1/19/2037 Granted
IN VITRO PRE-CONDITIONED BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AND USES THEREOF CON: Continuation United States 16/426,534 10,709,740 5/30/2019 7/14/2020 8/3/2036 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Anum Afzal
aafzal7@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum